Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323.
No abstract available

Publication types

  • Published Erratum